DE69433532D1 - Amphiphile imidazolinium-derivate - Google Patents

Amphiphile imidazolinium-derivate

Info

Publication number
DE69433532D1
DE69433532D1 DE69433532T DE69433532T DE69433532D1 DE 69433532 D1 DE69433532 D1 DE 69433532D1 DE 69433532 T DE69433532 T DE 69433532T DE 69433532 T DE69433532 T DE 69433532T DE 69433532 D1 DE69433532 D1 DE 69433532D1
Authority
DE
Germany
Prior art keywords
amphiphile
imidazolinium derivatives
amphiphiles
imidazolinium
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433532T
Other languages
English (en)
Other versions
DE69433532T2 (de
Inventor
D Heath
Igor Solodin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Juvaris Biotherapeutics Inc
Original Assignee
Klink Manfred
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klink Manfred filed Critical Klink Manfred
Publication of DE69433532D1 publication Critical patent/DE69433532D1/de
Application granted granted Critical
Publication of DE69433532T2 publication Critical patent/DE69433532T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
DE69433532T 1993-11-24 1994-11-17 Amphiphile imidazolinium-derivate Expired - Lifetime DE69433532T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15772793A 1993-11-24 1993-11-24
US157727 1993-11-24
US08/247,963 US5705655A (en) 1992-12-17 1994-05-24 Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
US247963 1994-05-24
PCT/US1994/013363 WO1995014380A1 (en) 1993-11-24 1994-11-17 Amphiphilic imidazolinium derivatives

Publications (2)

Publication Number Publication Date
DE69433532D1 true DE69433532D1 (de) 2004-03-11
DE69433532T2 DE69433532T2 (de) 2005-01-05

Family

ID=26854423

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433532T Expired - Lifetime DE69433532T2 (de) 1993-11-24 1994-11-17 Amphiphile imidazolinium-derivate

Country Status (11)

Country Link
US (2) US5705655A (de)
EP (1) EP0730404B1 (de)
JP (1) JP2918693B2 (de)
KR (1) KR100246839B1 (de)
AT (1) ATE258923T1 (de)
AU (1) AU691217B2 (de)
CA (1) CA2176713C (de)
DE (1) DE69433532T2 (de)
NO (1) NO305557B1 (de)
NZ (1) NZ276645A (de)
WO (1) WO1995014380A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5747471A (en) * 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US6093816A (en) * 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
US6121457A (en) * 1997-11-14 2000-09-19 Megabios Corporation Compositions and methods using novel substituted imidazolium lipids
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
ES2366100T3 (es) 1999-02-22 2011-10-17 Georgetown University Inmunoliposomas dirigidos mediante un fragmento de anticuerpo para la administración sistémica de genes.
WO2002078608A2 (en) * 2001-04-02 2002-10-10 Georgetown University A simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome or polyplex for systemic administration of a therapeutic or diagnostic agent
US7297712B2 (en) * 2002-03-27 2007-11-20 Council Of Scientific And Industrial Research Cationic amphiphiles for intracellular delivery of therapeutic molecules and its composition, process and method of treatment
AU2007257357B2 (en) 2006-05-15 2010-08-26 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US8044215B2 (en) * 2009-04-29 2011-10-25 Juvaris Biotherapeutics, Inc. Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds
GB2578557B (en) 2013-07-16 2020-09-02 Univ Leland Stanford Junior Enhancement of osteogenic potential of bone grafts
ES2901788T3 (es) * 2015-05-04 2022-03-23 Bayer Animal Health Gmbh Proceso para la preparación de compuestos anfifílicos de imidiazolinio

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945821A (en) * 1956-10-24 1960-07-19 Nalco Chemical Co Process of inhibiting corrosion
US3186912A (en) * 1959-08-03 1965-06-01 Robert L Beamer Cosmetic emulsion
US3210312A (en) * 1961-07-25 1965-10-05 Geigy Chem Corp Anti-electrostatic imidazoline salts for resin compositions
NL281319A (de) * 1961-07-25
US3205092A (en) * 1962-02-20 1965-09-07 Geigy Chem Corp Magnetic tape having improved antistatic properties
US3216957A (en) * 1962-08-14 1965-11-09 Union Carbide Corp Antistatic thermoplastic vinyl resin compositions comprising oxyalkylated imidazolines
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules

Also Published As

Publication number Publication date
CA2176713A1 (en) 1995-06-01
JPH09505594A (ja) 1997-06-03
AU691217B2 (en) 1998-05-14
US5705655A (en) 1998-01-06
WO1995014380A1 (en) 1995-06-01
DE69433532T2 (de) 2005-01-05
EP0730404B1 (de) 2004-02-04
ATE258923T1 (de) 2004-02-15
NO962073D0 (no) 1996-05-21
US5736395A (en) 1998-04-07
AU1099995A (en) 1995-06-13
NZ276645A (en) 1998-05-27
NO962073L (no) 1996-07-09
KR100246839B1 (ko) 2000-08-01
EP0730404A4 (de) 1997-02-19
JP2918693B2 (ja) 1999-07-12
NO305557B1 (no) 1999-06-21
CA2176713C (en) 2000-02-22
EP0730404A1 (de) 1996-09-11

Similar Documents

Publication Publication Date Title
DE69433532D1 (de) Amphiphile imidazolinium-derivate
MY115416A (en) Quinolone-and naphthyridone-carboxylic acid derivatives
PT82127A (en) Process for the preparation of phenyl carbamates
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
DK0758248T3 (da) Formuleringer til faktor IX
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
NO307459B1 (no) Piperazinderivater, samt farmasøytiske preparater inneholdende slike
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
MX9302116A (es) Compuestos azabiciclo.
FI924478A0 (fi) 24-oxa-derivat i vitamin d-serien
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
IL106748A0 (en) 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
ES2174113T3 (es) Nuevos derivados de ((3-alcoxi-fenoxi)-etil)-dialquilamina y su utilizacion como anestesicos locales.
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
ES2141978T3 (es) Retinoides triciclicos, metodos para su produccion y uso.
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
NO923266L (no) Heksahydrobenzo(f)quinolinoner
DE69320653T2 (de) Tetrahydrocarbazolderivate als 5-ht1-ähnliche agonisten
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
FI951092A0 (fi) Fluoreseiinijohdannaisten stabiilit korkeakonsentroidut valmisteet
NO932502D0 (no) Nye fosfolipidderivater
KR970006264A (ko) 신규한 6-치환-5, 8-디옥시-1, 4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도
FI934468A0 (fi) Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytesmellanprodukter
DE69215511D1 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
ZA922501B (en) Thid-carboxylic acid derivatives as collagenase inhibitors.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: JUVARIS BIOTHERAPEUTICS, INC. (N.D.GES. D. STA, US